NASDAQ:EGLT - Egalet Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.5140 +0.02 (+4.05 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$0.5140
Today's Range$0.4951 - $0.52
52-Week Range$0.47 - $3.47
Volume324,235 shs
Average Volume651,402 shs
Market Capitalization$27.18 million
P/E Ratio-0.21
Dividend YieldN/A
Beta0.68

About Egalet (NASDAQ:EGLT)

Egalet logoEgalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.

Receive EGLT News and Ratings via Email

Sign-up to receive the latest news and ratings for EGLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGLT
CUSIPN/A
Phone610-833-4200

Debt

Debt-to-Equity Ratio-3.00
Current Ratio2.29
Quick Ratio2.30

Price-To-Earnings

Trailing P/E Ratio-0.21
Forward P/E Ratio-0.54
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.14 million
Price / Sales1.04
Cash FlowN/A
Price / CashN/A
Book Value($0.62) per share
Price / Book-0.83

Profitability

EPS (Most Recent Fiscal Year)($2.44)
Net Income$-69,350,000.00
Net Margins-208.90%
Return on EquityN/A
Return on Assets-57.93%

Miscellaneous

Employees131
Outstanding Shares52,880,000

Egalet (NASDAQ:EGLT) Frequently Asked Questions

What is Egalet's stock symbol?

Egalet trades on the NASDAQ under the ticker symbol "EGLT."

How were Egalet's earnings last quarter?

Egalet (NASDAQ:EGLT) posted its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.03. The specialty pharmaceutical company had revenue of $6.26 million for the quarter, compared to analysts' expectations of $8.10 million. View Egalet's Earnings History.

When is Egalet's next earnings date?

Egalet is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Egalet.

What price target have analysts set for EGLT?

5 analysts have issued 12-month price targets for Egalet's shares. Their predictions range from $1.50 to $7.00. On average, they anticipate Egalet's stock price to reach $4.1250 in the next twelve months. View Analyst Ratings for Egalet.

Are investors shorting Egalet?

Egalet saw a drop in short interest in April. As of April 13th, there was short interest totalling 4,377,465 shares, a drop of 39.7% from the March 30th total of 7,263,420 shares. Based on an average daily volume of 355,419 shares, the days-to-cover ratio is presently 12.3 days. Currently, 11.5% of the shares of the company are short sold.

Who are some of Egalet's key competitors?

Who are Egalet's key executives?

Egalet's management team includes the folowing people:
  • Mr. Robert S. Radie, Pres, CEO & Director (Age 55)
  • Dr. Mark Strobeck, Exec. VP & COO (Age 47)
  • Mr. Patrick M. Shea, Sr. VP & Chief Commercial Officer (Age 53)
  • Mr. Stanley J. Musial, Exec. VP, CFO & Sec. (Age 57)
  • Ms. Barbara A. Carlin, Sr. VP & Chief Accounting Officer (Age 43)

Has Egalet been receiving favorable news coverage?

Media stories about EGLT stock have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Egalet earned a media sentiment score of 0.15 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 48.71 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Egalet?

Shares of EGLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Egalet's stock price today?

One share of EGLT stock can currently be purchased for approximately $0.5140.

How big of a company is Egalet?

Egalet has a market capitalization of $27.18 million and generates $26.14 million in revenue each year. The specialty pharmaceutical company earns $-69,350,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Egalet employs 131 workers across the globe.

How can I contact Egalet?

Egalet's mailing address is 600 LEE ROAD SUITE 100, WAYNE PA, 19087. The specialty pharmaceutical company can be reached via phone at 610-833-4200 or via email at [email protected]


MarketBeat Community Rating for Egalet (EGLT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  425
MarketBeat's community ratings are surveys of what our community members think about Egalet and other stocks. Vote "Outperform" if you believe EGLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Egalet (NASDAQ:EGLT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Egalet in the last 12 months. Their average twelve-month price target is $4.1250, suggesting that the stock has a possible upside of 702.53%. The high price target for EGLT is $7.00 and the low price target for EGLT is $1.50. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.402.602.602.80
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.1250$5.50$6.20$7.10
Price Target Upside: 702.53% upside587.50% upside501.94% upside755.42% upside

Egalet (NASDAQ:EGLT) Consensus Price Target History

Price Target History for Egalet (NASDAQ:EGLT)

Egalet (NASDAQ:EGLT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Cantor FitzgeraldDowngradeOverweight ➝ Hold$2.00LowView Rating Details
1/3/2018Stifel NicolausDowngradeBuy ➝ Hold$1.50HighView Rating Details
11/9/2017GabelliDowngradeBuy ➝ HoldN/AView Rating Details
8/14/2017GuggenheimSet Price TargetBuy$7.00HighView Rating Details
7/14/2017JMP SecuritiesLower Price TargetMarket Outperform$15.00 ➝ $6.00MediumView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Egalet (NASDAQ:EGLT) Earnings History and Estimates Chart

Earnings by Quarter for Egalet (NASDAQ:EGLT)

Egalet (NASDAQ:EGLT) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.67 EPS

Egalet (NASDAQ EGLT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018        
5/8/2018Q1 2018($0.29)($0.26)$8.10 million$6.26 millionViewN/AView Earnings Details
3/12/2018n/a($0.38)($0.27)$8.54 million$7.80 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.47)($0.46)$7.46 million$6.65 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.94)($1.04)$6.68 million$6.26 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.90)($1.02)$6.92 million$5.57 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.92)($0.87)$5.37 million$6.14 millionViewListenView Earnings Details
11/4/2016Q316($0.90)($1.10)$4.50 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($0.82)($0.97)$3.83 million$3.45 millionViewN/AView Earnings Details
5/10/2016Q116($0.87)($0.76)$3.50 million$2.70 millionViewListenView Earnings Details
3/8/2016Q415($0.91)($0.28)$2.80 million$2.10 millionViewN/AView Earnings Details
11/4/2015Q315($0.90)($0.81)$1.62 million$1.30 millionViewN/AView Earnings Details
8/6/2015Q215($1.02)($0.98)$0.95 million$0.96 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.98)($1.02)$3.00 million$0.81 millionViewN/AView Earnings Details
3/16/2015Q414($0.71)($0.52)$0.30 million$0.83 millionViewN/AView Earnings Details
11/12/2014Q314($0.75)($0.63)$0.35 millionViewN/AView Earnings Details
8/12/2014Q214($0.41)($0.73)$0.49 millionViewN/AView Earnings Details
5/13/2014Q114($0.16)($1.34)$0.26 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Egalet (NASDAQ:EGLT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Egalet (NASDAQ EGLT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 31.24%
Insider Trading History for Egalet (NASDAQ:EGLT)
Institutional Ownership by Quarter for Egalet (NASDAQ:EGLT)

Egalet (NASDAQ EGLT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Patrick M SheaInsiderSell910$1.00$910.0037,020View SEC Filing  
10/2/2017Mark StrobeckCOOSell8,700$1.29$11,223.0012,080View SEC Filing  
10/2/2017Patrick M SheaInsiderSell910$1.30$1,183.0037,930View SEC Filing  
7/3/2017Patrick M. SheaInsiderSell910$2.35$2,138.50View SEC Filing  
7/3/2017Paul VarkiSVPSell806$2.35$1,894.10View SEC Filing  
7/3/2017Stan MusialCFOSell3,480$2.36$8,212.8042,407View SEC Filing  
6/30/2017Mark StrobeckCOOSell8,700$2.39$20,793.0020,780View SEC Filing  
4/3/2017Paul VarkiSVPSell806$5.05$4,070.3028,820View SEC Filing  
4/3/2017Stan MusialCFOSell8,613$5.04$43,409.5245,887View SEC Filing  
3/31/2017Jeffrey M DaynoInsiderSell536$5.16$2,765.7618,212View SEC Filing  
3/31/2017Mark StrobeckCOOSell8,700$5.11$44,457.0029,480View SEC Filing  
3/20/2017Patrick M SheaInsiderSell4,250$4.75$20,187.5038,250View SEC Filing  
1/3/2017Jeffrey M DaynoInsiderSell536$7.75$4,154.0018,748View SEC Filing  
1/3/2017Paul VarkiSVPSell806$7.75$6,246.5029,626View SEC Filing  
1/3/2017Stan MusialCFOSell13,480$7.73$104,200.4054,500View SEC Filing  
12/30/2016Mark StrobeckCOOSell8,700$7.81$67,947.0038,180View SEC Filing  
10/3/2016Paul VarkiSVPSell806$7.56$6,093.3630,432View SEC Filing  
10/3/2016Robert S RadieInsiderSell15,000$7.47$112,050.00234,900View SEC Filing  
10/3/2016Stan MusialCFOSell13,480$7.47$100,695.6067,980View SEC Filing  
9/30/2016Jeffrey M DaynoInsiderSell536$7.69$4,121.8419,284View SEC Filing  
9/30/2016Mark StrobeckCOOSell33,700$7.58$255,446.0071,880View SEC Filing  
7/6/2016Robert S RadieCEOSell15,000$5.01$75,150.00259,900View SEC Filing  
7/5/2016Robert S RadieCEOSell5,000$4.94$24,700.00259,900View SEC Filing  
7/5/2016Stan MusialCFOSell13,480$5.06$68,208.8084,940View SEC Filing  
7/1/2016Robert S RadieCEOSell5,000$5.07$25,350.00259,900View SEC Filing  
7/1/2016Stan MusialCFOSell10,000$5.06$50,600.0084,940View SEC Filing  
6/30/2016Jeffrey M DaynoInsiderSell536$4.65$2,492.4019,820View SEC Filing  
4/5/2016Deanne F MelloyInsiderSell860$6.96$5,985.6033,420View SEC Filing  
4/5/2016Robert S RadieCEOSell5,000$6.99$34,950.00264,900View SEC Filing  
4/4/2016Robert S RadieCEOSell10,000$6.97$69,700.00274,900View SEC Filing  
1/11/2016Robert S. RadieCEOSell10,000$9.65$96,500.00279,900View SEC Filing  
1/6/2016Robert S. RadieCEOSell5,000$10.52$52,600.00298,900View SEC Filing  
10/6/2015Deanne F MelloyInsiderSell860$11.42$9,821.2035,140View SEC Filing  
10/1/2015Robert S RadieCEOSell15,000$12.27$184,050.00303,900View SEC Filing  
10/1/2015Stan MusialCFOSell8,480$12.32$104,473.60101,900View SEC Filing  
9/30/2015Mark StrobeckInsiderSell5,220$12.56$65,563.20106,680View SEC Filing  
7/8/2015Robert S RadieCEOSell6,000$11.97$71,820.00View SEC Filing  
7/6/2015Robert S RadieCEOSell9,000$12.53$112,770.00View SEC Filing  
7/1/2015Mark StrobeckInsiderSell10,440$12.98$135,511.20View SEC Filing  
7/1/2015Stan MusialCFOSell8,480$13.20$111,936.00View SEC Filing  
4/1/2015Robert S RadieCEOSell11,130$11.25$125,212.50View SEC Filing  
2/3/2015Jeffrey M DaynoInsiderSell2,500$8.87$22,175.00View SEC Filing  
1/2/2015Mark StrobeckInsiderSell3,480$5.09$17,713.20View SEC Filing  
1/2/2015Robert S RadieCEOSell11,130$5.11$56,874.30View SEC Filing  
9/10/2014Robert S RadieCEOSell40,040$9.61$384,784.40View SEC Filing  
9/8/2014Robert S RadieCEOSell49,000$9.74$477,260.00View SEC Filing  
8/13/2014Mark StrobeckInsiderSell5,135$9.20$47,242.00View SEC Filing  
8/11/2014Mark StrobeckInsiderSell5,700$10.28$58,596.00View SEC Filing  
8/7/2014Mark StrobeckInsiderSell3,085$11.50$35,477.50View SEC Filing  
8/7/2014Stan MusialCFOSell13,920$11.05$153,816.00View SEC Filing  
2/11/2014Jean Francois FormelaDirectorBuy41,667$12.00$500,004.00View SEC Filing  
2/11/2014Life Science Ventures SunstoneMajor ShareholderBuy133,333$12.00$1,599,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Egalet (NASDAQ EGLT) News Headlines

Source:
DateHeadline
Egalet (EGLT) Expected to Announce Quarterly Sales of $8.64 MillionEgalet (EGLT) Expected to Announce Quarterly Sales of $8.64 Million
www.americanbankingnews.com - May 18 at 5:01 AM
Breakeven On The Horizon For Egalet Corporation (NASDAQ:EGLT)Breakeven On The Horizon For Egalet Corporation (NASDAQ:EGLT)
finance.yahoo.com - May 17 at 9:10 AM
-$0.21 Earnings Per Share Expected for Egalet (EGLT) This Quarter-$0.21 Earnings Per Share Expected for Egalet (EGLT) This Quarter
www.americanbankingnews.com - May 16 at 5:27 AM
EGLT: Partnerships and Formulary Adds Impressive; Waiting for Revenue Catch UpEGLT: Partnerships and Formulary Adds Impressive; Waiting for Revenue Catch Up
finance.yahoo.com - May 14 at 4:51 PM
Egalets (EGLT) CEO Bob Radie on Q1 2018 Results - Earnings Call TranscriptEgalet's (EGLT) CEO Bob Radie on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 9:16 AM
Edited Transcript of EGLT earnings conference call or presentation 8-May-18 12:30pm GMTEdited Transcript of EGLT earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 9 at 9:07 AM
Egalet (EGLT) Downgraded by Cantor Fitzgerald to HoldEgalet (EGLT) Downgraded by Cantor Fitzgerald to Hold
www.americanbankingnews.com - May 8 at 3:28 PM
Egalet (EGLT) Releases  Earnings Results, Beats Expectations By $0.03 EPSEgalet (EGLT) Releases Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 8 at 12:13 PM
BRIEF-Egalet Reports Q1 Loss Per Share $0.26BRIEF-Egalet Reports Q1 Loss Per Share $0.26
www.reuters.com - May 8 at 9:05 AM
Egalet: 1Q Earnings SnapshotEgalet: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:05 AM
Egalet Reports First Quarter 2018 Financial ResultsEgalet Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 9:05 AM
Egalet (EGLT) Announces Coverage of SPRIX Nasal Spray and ARYMO ER by National Pharmacy Benefit ManagerEgalet (EGLT) Announces Coverage of SPRIX Nasal Spray and ARYMO ER by National Pharmacy Benefit Manager
www.streetinsider.com - May 7 at 9:47 AM
BRIEF-Egalet Corp Says A National Pharmacy Benefit Manager Has Placed Sprix Nasal Spray In A Tier 2 Preferred ...BRIEF-Egalet Corp Says A National Pharmacy Benefit Manager Has Placed Sprix Nasal Spray In A Tier 2 Preferred ...
www.reuters.com - May 7 at 9:47 AM
Egalet Announces National Pharmacy Benefit Manager to Cover SPRIX® Nasal Spray and ARYMO® EREgalet Announces National Pharmacy Benefit Manager to Cover SPRIX® Nasal Spray and ARYMO® ER
finance.yahoo.com - May 7 at 9:47 AM
Egalet to Present at the 3rd Annual Disruptive Growth & Healthcare ConferenceEgalet to Present at the 3rd Annual Disruptive Growth & Healthcare Conference
finance.yahoo.com - May 2 at 8:55 AM
Egalet (EGLT) Set to Announce Quarterly Earnings on TuesdayEgalet (EGLT) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 11:10 AM
Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid ...Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid ...
www.prnewswire.com - April 30 at 10:08 AM
Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid AbuseEgalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse
finance.yahoo.com - April 30 at 10:07 AM
Egalet (EGLT) Short Interest Down 39.7% in AprilEgalet (EGLT) Short Interest Down 39.7% in April
www.americanbankingnews.com - April 27 at 2:58 AM
Egalet (EGLT) Given Average Recommendation of "Hold" by BrokeragesEgalet (EGLT) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 26 at 3:32 AM
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on May 8, 2018Egalet to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on May 8, 2018
finance.yahoo.com - April 24 at 9:01 AM
Free Post Earnings Research Report: Egalets Q4 Top-Line Growth Beat EstimatesFree Post Earnings Research Report: Egalet's Q4 Top-Line Growth Beat Estimates
finance.yahoo.com - April 20 at 9:12 AM
BRIEF-Egalet Announces Two Large Regional Health Plans Placed Arymo® Er In Preferred Formulary PositionBRIEF-Egalet Announces Two Large Regional Health Plans Placed Arymo® Er In Preferred Formulary Position
www.reuters.com - April 17 at 4:55 PM
Egalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary PositionEgalet Announces Two Large Northeast Regional Health Plans Placed ARYMO® ER in Preferred Formulary Position
finance.yahoo.com - April 17 at 4:55 PM
Egalet (EGLT) Rating Reiterated by Stifel NicolausEgalet (EGLT) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - April 10 at 8:23 PM
Guggenheim Analysts Give Egalet (EGLT) a $7.00 Price TargetGuggenheim Analysts Give Egalet (EGLT) a $7.00 Price Target
www.americanbankingnews.com - April 10 at 6:07 PM
EGLT: Costs Down, Revenues Up, Partnerships ExpandingEGLT: Costs Down, Revenues Up, Partnerships Expanding
finance.yahoo.com - April 2 at 4:55 PM
Egalet (EGLT) Given Average Recommendation of "Hold" by AnalystsEgalet (EGLT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 1 at 3:24 AM
Egalet CEO: We are moving the company closer and closer to profitability - Philadelphia Business JournalEgalet CEO: 'We are moving the company closer and closer to profitability' - Philadelphia Business Journal
www.bizjournals.com - March 24 at 8:20 AM
Egalet CEO: 'We are moving the company closer and closer to profitability'Egalet CEO: 'We are moving the company closer and closer to profitability'
finance.yahoo.com - March 23 at 6:14 PM
Auditor raises questions about Egalets future - Philadelphia Business JournalAuditor raises questions about Egalet's future - Philadelphia Business Journal
www.bizjournals.com - March 22 at 5:03 PM
Egalet to Present at Upcoming Conferences - PR Newswire (press release)Egalet to Present at Upcoming Conferences - PR Newswire (press release)
www.prnewswire.com - March 22 at 5:03 PM
Auditor raises questions about Egalet's futureAuditor raises questions about Egalet's future
finance.yahoo.com - March 22 at 5:03 PM
[$$] Drug Maker Egalet Raises Going Concern warning[$$] Drug Maker Egalet Raises 'Going Concern' warning
finance.yahoo.com - March 22 at 5:03 PM
Egalet to Present at Upcoming ConferencesEgalet to Present at Upcoming Conferences
finance.yahoo.com - March 21 at 9:34 AM
Edited Transcript of EGLT earnings conference call or presentation 12-Mar-18 12:30pm GMTEdited Transcript of EGLT earnings conference call or presentation 12-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 9:30 AM
Equities Analysts Offer Predictions for Egalet Corps FY2018 Earnings (EGLT)Equities Analysts Offer Predictions for Egalet Corp's FY2018 Earnings (EGLT)
www.americanbankingnews.com - March 16 at 10:42 AM
Egalet Corp (EGLT) Expected to Earn FY2019 Earnings of ($0.70) Per ShareEgalet Corp (EGLT) Expected to Earn FY2019 Earnings of ($0.70) Per Share
www.americanbankingnews.com - March 15 at 12:58 PM
Egalet (EGLT) Price Target Cut to $3.50Egalet (EGLT) Price Target Cut to $3.50
www.americanbankingnews.com - March 13 at 11:49 AM
Egalet posts 4Q profitEgalet posts 4Q profit
finance.yahoo.com - March 12 at 4:51 PM
Egalet Reports Fourth Quarter and Full Year 2017 Financial ResultsEgalet Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 4:51 PM
Cantor Fitzgerald Reiterates "$4.00" Price Target for Egalet (EGLT)Cantor Fitzgerald Reiterates "$4.00" Price Target for Egalet (EGLT)
www.americanbankingnews.com - March 12 at 3:14 PM
Egalet (EGLT) Releases  Earnings Results, Beats Estimates By $0.19 EPSEgalet (EGLT) Releases Earnings Results, Beats Estimates By $0.19 EPS
www.americanbankingnews.com - March 12 at 12:10 PM
Egalet Corp (EGLT) Expected to Announce Quarterly Sales of $8.54 MillionEgalet Corp (EGLT) Expected to Announce Quarterly Sales of $8.54 Million
www.americanbankingnews.com - March 10 at 12:43 PM
Egalet Corp (EGLT) Receives Consensus Rating of "Hold" from BrokeragesEgalet Corp (EGLT) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 7 at 3:26 AM
Egalet (EGLT) to Release Quarterly Earnings on MondayEgalet (EGLT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - March 5 at 3:28 AM
Egalet Announces a Large Regional Health Plan Placed ARYMO® ER and SPRIX® Nasal Spray in Preferred Formulary PositionsEgalet Announces a Large Regional Health Plan Placed ARYMO® ER and SPRIX® Nasal Spray in Preferred Formulary Positions
finance.yahoo.com - February 28 at 9:34 AM
Egalet to Host Conference Call and Webcast to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 12, 2018Egalet to Host Conference Call and Webcast to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 12, 2018
finance.yahoo.com - February 26 at 4:48 PM
$8.54 Million in Sales Expected for Egalet Corp (EGLT) This Quarter$8.54 Million in Sales Expected for Egalet Corp (EGLT) This Quarter
www.americanbankingnews.com - February 21 at 4:12 AM
Egalet (EGLT) Reports Issuance of New U.S. Patent for Guardian TechnologyEgalet (EGLT) Reports Issuance of New U.S. Patent for Guardian Technology
www.streetinsider.com - February 20 at 8:46 AM

SEC Filings

Egalet (NASDAQ:EGLT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Egalet (NASDAQ:EGLT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Egalet (NASDAQ EGLT) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.